Bruce Booth

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Waltham, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Ommer Chohan, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Bruce Booth

Form 4 holding Director

Vigil Neuroscience, Inc.

Security class
Stock Option Award (Right to Buy)
Shares / value
0
Estimated value
$137,642
Report date
05 Aug 2025
Price
$7.62
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Magenta Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
20,000
Estimated value
Report date
28 Jun 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Sionna Therapeutics, Inc.

Security class
Non-Qualified Stock Option (right to buy)
Shares / value
19,959
Estimated value
Report date
12 Jun 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

AVROBIO, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
17,643
Estimated value
Report date
06 Jun 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Sionna Therapeutics, Inc.

Security class
Series A convertible preferred stock
Shares / value
0
Estimated value
Report date
10 Feb 2025
Price
Ownership
By Atlas Venture Fund XI, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Sionna Therapeutics, Inc.

Security class
Series B convertible preferred stock
Shares / value
0
Estimated value
Report date
10 Feb 2025
Price
Ownership
By Atlas Venture Fund XI, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Sionna Therapeutics, Inc.

Security class
Series C convertible preferred stock
Shares / value
0
Estimated value
Report date
10 Feb 2025
Price
Ownership
By Atlas Venture Fund XI, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Sionna Therapeutics, Inc.

Security class
Series C convertible preferred stock
Shares / value
0
Estimated value
Report date
10 Feb 2025
Price
Ownership
By Atlas Venture Opportunity Fund II, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Sionna Therapeutics, Inc.

Security class
Series Seed convertible preferred stock
Shares / value
0
Estimated value
Report date
10 Feb 2025
Price
Ownership
By Atlas Venture Fund XI, L.P.
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Bruce Booth

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .